A Phase IV Open-Label Clinical Trial to Evaluate the Efficacy of Ikervis® on Clinical Parameters and Molecular/Cellular Biomarkers in Dry Eye Patients With Severe Keratitis Who Have Not Improved Despite Regular Use of Tear Substitutes Before and After Exposure to an Adverse Controlled Environment

Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA1 site in 1 country25 target enrollmentFebruary 4, 2020

ConditionsDry Eye Dry Eye Syndromes Severe Keratitis

InterventionsIKERVIS®1mg/mL

DrugsIKERVIS®1mg/mL

Overview

Phase: Phase 4
Intervention: IKERVIS®1mg/mL
Conditions: Dry Eye
Sponsor: Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Enrollment: 25
Locations: 1
Primary Endpoint: Corneal fluoresceing staining
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The proposed study is a prospective, open-label, unicentric, phase IV clinical trial.

This study is design to find new efficacy biomarkers for IKERVIS® (1mg/mL ciclosporin) eye drops after 1 and 3 month after initiation of therapy. Additionally, this study intends to investigate whether IKERVIS® will help patients to better overcome situations of desiccating stress by exposing them to an adverse controlled environment (ACE) and analyzing both clinical and molecular parameters.

Registry

clinicaltrials.gov

Start Date

February 4, 2020

End Date

January 18, 2021

Last Updated

5 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age \> 18 years.
•Diagnosis of DED with Severe Keratitis who have not improved despite regular use of tear substitutes by an ophthalmologist, at least 2 months previously.
•Not stable (as defined by the two items below) under at least 2 months of constant and regular use of artificial tears (at least 4 drops a day)
•Fluorescein corneal staining ≥ 2 (Oxford scale) in both eyes.
•DEQ-5 \> 6 points
•Use of at least 4 times daily of an ocular artificial tears.
•Any concomitant medication that may affect DED, ocular surface condition or vision, must have a start date at least 3 months prior to baseline and dosage is not expected to change during the study.
•Best corrected visual acuity (BCVA) of at least 0.1 logMar at 6 meters with each eye.
•Signature of written informed consent form and data protection form.

Exclusion Criteria

•Known allergy or sensitivity to the study product(s) or its components.
•Any ocular pathology other than DED.
•History of severe ocular inflammation other than that due to DED or infection in the 6 previous months to the study inclusion.
•Any ocular surgery or trauma that may affect corneal sensitivity and/or normal tear distribution in the 6 previous months or any ocular or systemic surgery or procedure planned during the study duration that may affect the study as assessed by principal investigator.
•History of refractive surgery in the previous 18 months.
•Contact lens use in the ONE previous month to study inclusion and during the duration of the study.
•Use of any ocular topical medication for pathologies other than DED.
•Use of any other ocular topical medication for DED other than artificial tears during the last ONE (steroids) or THREE months (ciclosporine, tacrolimus) .
•Any uncontrolled severe systemic disease that may affect the eye (except for Sjögren's syndrome)
•The start date of any systemic medication that may affect DED, ocular surface condition or vision is \< 3 months prior to baseline or a change in dosage is anticipated during the study.

Arms & Interventions

IKERVIS® (1mg/mL ciclosporin) eye drops

Intervention: IKERVIS®1mg/mL

Outcomes

Primary Outcomes

Corneal fluoresceing staining

Time Frame: V1 (baseline) vs V2 (30 days of treatment); V1 (baseline) vs V3 (90 days of treatment); V2 (30 days of treatment) vs V3 (90 days of treatment)

Significant reduction in corneal fluorescein staining

Secondary Outcomes

Response against adverse environmental conditions(V1 (baseline) vs V2 (30 days of treatment); V1 (baseline) vs V3 (90 days of treatment))
Molecular changes(V1 (baseline) vs V2 (30 days of treatment); V1 (baseline) vs V3 (90 days of treatment))